

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MICROPORT CARDIOFLOW MEDTECH CORPORATION

微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

FURTHER ANNOUNCEMENT IN RELATION TO DISCLOSEABLE TRANSACTION — LEASING OF PROPERTIES

Reference is made to the announcement of the Company dated May 13, 2021 (the “**Announcement**”) in relation to the Lease Agreement entered into by Shanghai CardioFlow, a wholly-owned subsidiary of the Company, for the leasing of the Property. Unless otherwise provided, capitalised terms used in this announcement shall have the same meaning as those used in the Announcement.

The Company would like to provide the following additional information with regard to the Lease Agreement for the reference of the Shareholders and investors.

Term of the Lease Agreement

The Lease Agreement has a term of five years, commencing on May 16, 2021 and ending on May 15, 2026.

Use of the Property

The Property will be used by the Group for production function for the Group’s expansion plan.

Information on the Property

The Property is part of a purpose built industrial facility developed by the Landlord. It is located at No. 1661, Zhangdong Road, the China (Shanghai) Pilot Free Trade Zone (中國(上海)自由貿易試驗區張東路1661號), which has a total gross floor area of approximately 15,503.54 sq.m..

Reasons for and benefits of the Lease Agreement

The Property is a purposely built facility for the operation of the Group. As construction of the Property had been completed, the Lease Agreement was entered into to enable the Group to use the Property.

As the rent for the Lease Agreement was determined with reference to prevailing market rate and that the terms of the Lease Agreement were concluded based on normal commercial terms, the Directors are of the view that the Lease Agreement was entered into on normal commercial terms and that the terms of which are fair and reasonable and are in the interests of the Company and the Shareholders as a whole.

Information on the Company and Shanghai CardioFlow

The Company is a medical device company in China focusing on the research, development and commercialization of innovative transcatheter and surgical solutions for valvular heart diseases.

Shanghai CardioFlow is a limited liability company established in the PRC and is a wholly-owned subsidiary of the Company. It is principally engaged in the manufacture, distribution, research and development of heart valve devices.

Information on the Landlord

As disclosed in the Announcement, the Landlord is a limited liability company established in the PRC and is principally engaged in investment management, investment consulting, production and sales of precision machinery, biomedical intermediates, research and development of high-tech products and related technical services, import and export of goods and technology, leasing of non-residential properties. It is an indirect subsidiary of Real & Realistic Foundation Limited (“**Real & Realistic**”). To the best knowledge of the Company, Real & Realistic is a company limited by guarantee with no share capital incorporated in Hong Kong. It is a charity foundation that focuses on advancing and promoting science and education and has no beneficial owners and ultimate controllers. The current directors of Real & Realistic are Mr. Tu Xianni (塗先妮), Mr. Xu Binkai (徐彬凱) and Mr. Chen Wei (陳偉).

By Order of the Board
MicroPort CardioFlow Medtech Corporation
Luo Qiyi
Chairman

Shanghai, the PRC, June 11, 2021

As of the date of this announcement, the executive Directors are Mr. Chen Guoming, Ms. Yan Luying and Mr. Wu Guojia, the non-executive Directors are Dr. Luo Qiyi, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Jiang Hualiang and Ms. Sun Zhixiang.